Sign In to View Organizational & Contract Pricing.
Select a Size
About This Item
Empirical Formula (Hill Notation):
C4H10NO5P · xNa+ · yH2O
CAS Number:
Molecular Weight:
183.10 (anhydrous free acid basis)
MDL number:
UNSPSC Code:
12352200
NACRES:
NA.77
Quality Level
assay
≥95% (NMR)
form
powder
storage condition
desiccated
color
white to beige
solubility
H2O: 20 mg/mL, clear
storage temp.
−20°C
SMILES string
[P](=O)(O)(O)CCCN(O)C=O
InChI
1S/C4H10NO5P/c6-4-5(7)2-1-3-11(8,9)10/h4,7H,1-3H2,(H2,8,9,10)
InChI key
GJXWDTUCERCKIX-UHFFFAOYSA-N
Related Categories
Application
Fosmidomycin sodium salt hydrate has been used as an inhibitor of 1-deoxy-D-xylulose 5-phosphate reductoisomerase in a study to determine monotropin carvacrol biosynthesis in Satureja khuzistanica plant.
Biochem/physiol Actions
Fosmidomycin is an inhibitor of 1-deoxy-D-xylulose 5-phosphate reductoisomerase (DXR) (MEP synthase): an antimalarial compound.
Fosmidomycin is an inhibitor of 1-deoxy-D-xylulose 5-phosphate reductoisomerase (DXR) (MEP synthase): an antimalarial compound. 1-deoxy-D-xylulose 5-phosphate reductoisomerase (DXR) is an enzyme involved in the first step in the nonmevalonate pathway for isoprenoid biosynthesis in Gram-negative, Gram-positive bacteria, plants, and the parasite causing the most virulent form of malaria, Plasmodium falciparum (Mammals produce isoprenoids via the mevalonate pathway).
Storage Class
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Christoph T Behrendt et al.
Journal of medicinal chemistry, 54(19), 6796-6802 (2011-08-27)
Reverse hydroxamate-based inhibitors of IspC, a key enzyme of the non-mevalonate pathway of isoprenoid biosynthesis and a validated antimalarial target, were synthesized and biologically evaluated. The binding mode of one derivative in complex with EcIspC and a divalent metal ion
Karin Brücher et al.
Journal of medicinal chemistry, 55(14), 6566-6575 (2012-06-27)
Specific inhibition of enzymes of the non-mevalonate pathway is a promising strategy for the development of novel antiplasmodial drugs. α-Aryl-substituted β-oxa isosteres of fosmidomycin with a reverse orientation of the hydroxamic acid group were synthesized and evaluated for their inhibitory
Miguel Lanaspa et al.
Antimicrobial agents and chemotherapy, 56(6), 2923-2928 (2012-03-21)
The combination of fosmidomycin and clindamycin (F/C) is effective in adults and older children for the treatment of malaria and could be an important alternative to existing artemisinin-based combinations (ACTs) if proven to work in younger children. We conducted an
Sarah Ponaire et al.
European journal of medicinal chemistry, 51, 277-285 (2012-03-13)
Since Mycobacterium tuberculosis sets up several multiple anti-tuberculosis drug resistance mechanisms, development of new drugs with innovative target is urgent. The methylerythritol phosphate pathway (MEP) involved in the biosynthesis of essential metabolites for the survival of mycobacteria, represents such a
Jan-Ytzen van der Meer et al.
Natural product reports, 29(7), 721-728 (2012-05-05)
Due to the increase in resistance of Plasmodium spp. against available antimalarials, there is a need for new, effective and innovative drugs. The non-mevalonate pathway for the biosynthesis of the universal isoprenoid precursors, which is absent in humans, is suggested
Global Trade Item Number
| SKU | GTIN |
|---|---|
| F8682-25MG | 04061832785462 |
| F8682-5MG | 04061833620953 |
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service